| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6011007 | NOVO NORDISK INC | Acylated insulin |
Feb, 2014
(10 years ago) | |
| US6869930 | NOVO NORDISK INC | Acylated insulin |
Feb, 2014
(10 years ago) | |
| US5750497 | NOVO NORDISK INC | Acylated insulin |
Jun, 2019
(4 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5866538 | NOVO NORDISK INC | Insulin preparations containing NaCl |
Jun, 2017
(6 years ago) | |
| USRE43834 | NOVO NORDISK INC | Injection syringe |
Jan, 2019
(5 years ago) | |
| US6004297 | NOVO NORDISK INC | Injection syringe |
Jan, 2019
(5 years ago) | |
| USRE41956 | NOVO NORDISK INC | Dose setting limiter |
Jan, 2021
(3 years ago) | |
| US9265893 | NOVO NORDISK INC | Injection button |
Sep, 2032
(8 years from now) | |
Levemir Flexpen is owned by Novo Nordisk Inc.
Levemir Flexpen contains Insulin Detemir Recombinant.
Levemir Flexpen has a total of 8 drug patents out of which 7 drug patents have expired.
Expired drug patents of Levemir Flexpen are:
- US5866538
- USRE43834
- US6004297
- USRE41956
- US6011007
- US6869930
- US5750497
Levemir Flexpen was authorised for market use on 31 October, 2013.
Levemir Flexpen is available in injectable;subcutaneous dosage forms.
Levemir Flexpen can be used as levemir is a long-acting basal insulin analog that is indicated in the treatment of patients with diabetes mellitus.
The generics of Levemir Flexpen are possible to be released after 23 September, 2032.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-117) | May 18, 2015 |
| M(M-115) | Apr 06, 2015 |
Drugs and Companies using INSULIN DETEMIR RECOMBINANT ingredient
Market Authorisation Date: 31 October, 2013
Treatment: Levemir is a long-acting basal insulin analog that is indicated in the treatment of patients with diabetes mellitus
Dosage: INJECTABLE;SUBCUTANEOUS
LEVEMIR FLEXPEN family patents
